Insulet (NASDAQ:PODD) Posts Quarterly Earnings Results, Beats Estimates By $0.07 EPS

Insulet (NASDAQ:PODD) issued its quarterly earnings results on Wednesday. The medical instruments supplier reported $1.55 earnings per share for the quarter, beating analysts’ consensus estimates of $1.48 by $0.07, FiscalAI reports. Insulet had a return on equity of 24.90% and a net margin of 9.12%.The business had revenue of $783.80 million during the quarter, compared to the consensus estimate of $768.31 million. During the same period in the previous year, the business earned $1.15 EPS. The business’s quarterly revenue was up 31.2% on a year-over-year basis.

Here are the key takeaways from Insulet’s conference call:

• Insulet finished 2025 with strong top-line momentum — Q4 revenue of $784M (29% constant-currency growth) and full-year revenue above $2.7B, marking the company’s 10th consecutive year of ≥20% constant-currency revenue growth.
• The company reported record new customer starts globally (with U.S. Type 2 representing >40% of Q4 starts and ~85% of U.S. starts coming from MDI conversions), while expanding prescriber reach to ~30,000 clinicians and maintaining pharmacy access in ~48,000 stores covering >90% of insured lives.
• Profitability and cash generation improved — 2025 gross margin was ~71.6% with ~270 bps of operating margin expansion year-over-year, adjusted EPS and free cash flow increased (>$375M), and the board authorized a $350M buyback with ~$300M expected to be deployed in Q1 2026.
• Insulet is investing heavily in its product roadmap — accelerating integrations (Dexcom G7, FreeStyle Libre 3 Plus), rolling out Omnipod Discover, advancing Omnipod Six (pivotal data at ADA) and a fully closed-loop program for Type 2 (pivotal planned in 2026; filing 2027; commercial 2028) — which supports long-term upside but entails elevated R&D spend.
• 2026 guidance implies some near-term deceleration (Omnipod revenue growth guidance 21%–23%, total company 20%–22%), driven by tougher comps and annualizing launches, with higher interest expense (~$40M) and free cash flow expected to be roughly flat versus 2025.

Insulet Price Performance

Shares of PODD opened at $249.10 on Friday. Insulet has a one year low of $230.05 and a one year high of $354.88. The stock’s fifty day moving average is $273.52 and its 200-day moving average is $305.11. The company has a debt-to-equity ratio of 0.61, a quick ratio of 2.18 and a current ratio of 2.81. The firm has a market capitalization of $17.52 billion, a price-to-earnings ratio of 71.17, a price-to-earnings-growth ratio of 1.46 and a beta of 1.41.

Key Stories Impacting Insulet

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Company beat Q4 EPS and revenue estimates, delivered ~31% revenue growth year‑over‑year, reported margin expansion and gave an upbeat 2026 outlook — this explains the initial surge in the stock after results. Insulet (PODD) Tops Q4 Earnings and Revenue Estimates
• Positive Sentiment: Insulet expanded its share repurchase program alongside the strong Q4 print — buybacks are typically supportive to equity value and were highlighted by management. Insulet Posts Strong Q4 Results, Expands Share Repurchase Program
• Positive Sentiment: Multiple brokers reaffirmed buy/overweight stances (BTIG reiterated Buy with a $380 PT; other firms maintained constructive views), supporting medium‑term investor confidence. BTIG Research Reiterates “Buy” Rating for Insulet (NASDAQ:PODD)
• Neutral Sentiment: Coverage remains broadly bullish overall (several analysts kept buy/outperform ratings), but some firms updated their models after the print — expect divergent price targets and advice in the near term. What Are Wall Street Analysts’ Target Price for Insulet Stock?
• Neutral Sentiment: Short‑interest reporting in the feed is noisy/garbled (shows 0 shares and 0 days‑to‑cover) — no clear signal from short activity based on the provided data. (No external link available.)
• Negative Sentiment: Several major brokers trimmed price targets after the results (Citigroup cut to $345, JPMorgan to $340, Leerink to $360) — even with maintained buy/overweight ratings, lower targets create pressure on near‑term upside expectations and may have contributed to profit‑taking. Benzinga coverage of analyst price target changes

Analysts Set New Price Targets

A number of analysts have weighed in on the stock. Truist Financial dropped their target price on shares of Insulet from $390.00 to $360.00 and set a “buy” rating on the stock in a report on Thursday. Wolfe Research increased their price objective on shares of Insulet from $350.00 to $375.00 and gave the stock an “outperform” rating in a research note on Friday, November 7th. BTIG Research restated a “buy” rating and issued a $380.00 target price on shares of Insulet in a research note on Wednesday. Leerink Partners dropped their price target on Insulet from $386.00 to $360.00 and set an “outperform” rating on the stock in a research report on Thursday. Finally, UBS Group reissued a “buy” rating on shares of Insulet in a report on Thursday, December 18th. Twenty equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $356.00.

Hedge Funds Weigh In On Insulet

Large investors have recently bought and sold shares of the stock. RTW Investments LP acquired a new stake in shares of Insulet in the 4th quarter worth approximately $92,264,000. AQR Capital Management LLC lifted its position in Insulet by 161.6% in the fourth quarter. AQR Capital Management LLC now owns 459,115 shares of the medical instruments supplier’s stock worth $130,499,000 after purchasing an additional 283,643 shares during the period. Worldquant Millennium Advisors LLC bought a new position in Insulet during the 2nd quarter valued at $80,082,000. Squarepoint Ops LLC boosted its stake in Insulet by 11,905.8% during the 3rd quarter. Squarepoint Ops LLC now owns 227,270 shares of the medical instruments supplier’s stock valued at $70,165,000 after purchasing an additional 225,377 shares in the last quarter. Finally, Qube Research & Technologies Ltd raised its stake in shares of Insulet by 37.3% in the 3rd quarter. Qube Research & Technologies Ltd now owns 574,365 shares of the medical instruments supplier’s stock worth $177,324,000 after buying an additional 156,009 shares in the last quarter.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.